The abstract is read at the publisher; the summary is JClub's.
In a US multidisciplinary gender clinic cohort, decisional regret after initiating estrogen or testosterone as youth was very low (mean DRS 4.3 [14.7]; median 0 [0–0]).
- Why it matters: Restrictions on hormone therapy for transgender and gender-diverse youth persist due to concerns about regret and perceived harm, but empirical data on decisional regret after starting therapy as youth are limited.
- What they did: A cohort study surveyed former patients from October 2023 to October 2025, analyzing Decision Regret Scale (0–100) scores and item-level satisfaction, regret, and perceived harm, with subgroup comparisons by current HT status.
- The result: Among 372 respondents with DRS scores, 96.8% said receiving HT was the right decision, 2.7% reported regret, and 1.9% reported perceived harm; DRS was higher in those not currently receiving HT and among nonbinary participants.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.